• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21045 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Dental bridges for partial tooth loss
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023     WorkSafeBC Cold plunges as treatment for concussions
2023     WorkSafeBC Flotation therapy as treatment for concussions
2023     WorkSafeBC Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023     WorkSafeBC Causal association between COVID-19 infection and irritable larynx syndrome
2023     WorkSafeBC Migraines and the (Moderna) COVID-19 vaccine
2023     WorkSafeBC Botulinum toxin as treatment for neck strains
2023     WorkSafeBC Esketamine as treatment for depression and PTSD
2023     WorkSafeBC Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023     WorkSafeBC Causal association between carpal tunnel release surgery and trigger finger
2023     WorkSafeBC Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: models for coordinating interhospital transfers in critical care]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2023     Health Technology Wales (HTW) Control contact lenses and spectacles for the treatment of myopia in children
2023     Health Information and Quality Authority (HIQA) Methods for generic justification of new practices in ionising radiation
2023     Health Information and Quality Authority (HIQA) Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023     Health Information and Quality Authority (HIQA) Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023     NIHR Health Technology Assessment programme Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: implantable medical device tracking methods]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Economic dimensions of community nursing: A systematic literature review]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for gallbladder removal]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Second Addendum to Commission A23-03]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tabelecleucel (relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), pretreated, 2 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) – Addendum to Commission A23-06]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Addendum to Commission A23-03]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of healthcare services by people with confirmed SARS-CoV-2 infection and those with no documented evidence of infection]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pediatric cancer predisposition using next-generation sequencing panels]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023     Norwegian Institute of Public Health (NIPH) [Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Invasive electroencephalography for drug-resistant epilepsy]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Triple-phase computed tomography in patients with liver lesion]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Sapropterin in patients with phenylketonuria]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Holmium laser in non-prostate endourologic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty and stenting in patients with carotid artery stenosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in psychiatry]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in respirology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in pediatrics]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in neurology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in internal medicine]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in hematology/oncology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in general surgery]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023     Health Information and Quality Authority (HIQA) Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023     Health Information and Quality Authority (HIQA) Interventions to improve long COVID symptoms: a systematic review